Whitehawk Therapeutics, Inc. (3350)
XDUS
Delayed Data
Oct 14, 2026, 06:00 AM
Day's Range
2.6252 wk Range
1.65Overview - 3350 - Whitehawk Therapeutics, Inc.
Key Statistics
Valuation
P/E (Trailing)
‪-9.93‬
PEG Ratio
‪0.13‬
Price / Book
‪1.48‬
Profitability
Profit Margin
‪89.36%‬
Operating Margin
‪-288.25%‬
Return on Assets
‪-13.65%‬
Return on Equity
‪-15.10%‬
Ownership
Shares Outstanding
57.00M
Price stats
50-Day Avg
‪3.66‬
200-Day Avg
‪3.21‬
Peers - 3350 - Whitehawk Therapeutics, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on XDUS.
- 3350XDUSWhitehawk Therapeutics, Inc.+51.22%52-week change-9.94P/E (Trailing)‪89.36%‬Profit Margin
- 0QFXDUSModerna Inc.+88.57%52-week change—P/E (Trailing)—Profit Margin
- 2LBXDUSIovance Biotherapeutics Inc.+83.47%52-week change-10.55P/E (Trailing)‪34.27%‬Profit Margin
- 0MEXDUSTwist Bioscience Corporation+80.08%52-week change-108.42P/E (Trailing)‪50.72%‬Profit Margin
- 3920XDUSSpyre Therapeutics, Inc.+76.32%52-week change-38.38P/E (Trailing)—Profit Margin
- 42ZXDUSRevolution Medicines, Inc.+75.52%52-week change-28.70P/E (Trailing)—Profit Margin
- 26CAXDUSImmunityBio Inc.+74.71%52-week change-22.00P/E (Trailing)‪99.33%‬Profit Margin
Profile Summary - 3350 - Whitehawk Therapeutics, Inc.
About
Whitehawk Therapeutics, Inc. is a clinical-stage oncology therapeutics company focused on developing antibody-drug conjugate (ADC) cancer treatments. Its current portfolio centers on three ADC assets designed to target clinically validated proteins across multiple tumor types, with emphasis on difficult-to-treat…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
